Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A.
暂无分享,去创建一个
Chin-Hsien Tai | Byungkook Lee | Ronit Mazor | Ira Pastan | I. Pastan | Chin-Hsien Tai | Byungkook Lee | R. Mazor
[1] Bjoern Peters,et al. Evaluating the Immunogenicity of Protein Drugs by Applying In Vitro MHC Binding Data and the Immune Epitope Database and Analysis Resource , 2013, Clinical & developmental immunology.
[2] I. Pastan,et al. Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome , 2014, British journal of haematology.
[3] H. Sbai,et al. Use of T cell epitopes for vaccine development. , 2001, Current drug targets. Infectious disorders.
[4] Andrew R. Jones,et al. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations , 2010, Nucleic Acids Res..
[5] U. Şahin,et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices , 1999, Nature Biotechnology.
[6] Ravi V. Kolla,et al. T Cell Responses to Known Allergen Proteins Are Differently Polarized and Account for a Variable Fraction of Total Response to Allergen Extracts , 2012, The Journal of Immunology.
[7] Leonard Moise,et al. A Method for Individualizing the Prediction of Immunogenicity of Protein Vaccines and Biologic Therapeutics: Individualized T Cell Epitope Measure (iTEM) , 2010, Journal of biomedicine & biotechnology.
[8] Leonard Moise,et al. Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo. , 2012, Clinical immunology.
[9] Vibha Jawa,et al. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. , 2013, Clinical immunology.
[10] T. Strutt,et al. Expanding roles for CD4+ T cells in immunity to viruses , 2012, Nature Reviews Immunology.
[11] W. Paul,et al. CD4 T cells: fates, functions, and faults. , 2008, Blood.
[12] R. Spielman,et al. Structure, Sequence and Polymorphism in the HLA‐D Region , 1985, Immunological reviews.
[13] E. Wardelmann,et al. HLA‐class II haplotype associations with ovarian cancer , 2006, International journal of cancer.
[14] Ravi V. Kolla,et al. Previously undescribed grass pollen antigens are the major inducers of T helper 2 cytokine-producing T cells in allergic individuals , 2013, Proceedings of the National Academy of Sciences.
[15] Morten Nielsen,et al. Quantitative Predictions of Peptide Binding to Any HLA-DR Molecule of Known Sequence: NetMHCIIpan , 2008, PLoS Comput. Biol..
[16] Bjoern Peters,et al. Molecular Determinants of T Cell Epitope Recognition to the Common Timothy Grass Allergen , 2010, The Journal of Immunology.
[17] J. Sidney,et al. In Silico Prediction of Peptides Binding to Multiple HLA-DR Molecules Accurately Identifies Immunodominant Epitopes from gp43 of Paracoccidioides brasiliensis Frequently Recognized in Primary Peripheral Blood Mononuclear Cell Responses from Sensitized Individuals , 2003, Molecular medicine.
[18] Morten Nielsen,et al. Peptide binding predictions for HLA DR, DP and DQ molecules , 2010, BMC Bioinformatics.
[19] Jing Wu,et al. In Silico Prediction of T and B Cell Epitopes of Der f 25 in Dermatophagoides farinae , 2014, International journal of genomics.
[20] P. Stordeur,et al. Monitoring of cellular responses after vaccination against tetanus toxoid: comparison of the measurement of IFN-gamma production by ELISA, ELISPOT, flow cytometry and real-time PCR. , 2005, Journal of immunological methods.
[21] Bjoern Peters,et al. Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes , 2011, Immunogenetics.
[22] B. Jabri,et al. Vaccine against autoimmune disease: antigen-specific immunotherapy. , 2013, Current opinion in immunology.
[23] Qing Zhang,et al. Immune epitope database analysis resource (IEDB-AR) , 2008, Nucleic Acids Res..
[24] I. Pastan,et al. Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers , 2007, Clinical Cancer Research.
[25] John Sidney,et al. Identification of novel consensus CD4 T-cell epitopes from clade B HIV-1 whole genome that are frequently recognized by HIV-1 infected patients , 2006, AIDS.
[26] B. Maillère,et al. Quantitative analysis of the CD4 T‐cell repertoire specific to therapeutic antibodies in healthy donors , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[27] Bernhard Knapp,et al. Specificities of Human CD4+ T Cell Responses to an Inactivated Flavivirus Vaccine and Infection: Correlation with Structure and Epitope Prediction , 2014, Journal of Virology.
[28] George Georgiou,et al. Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift , 2011, Proceedings of the National Academy of Sciences.
[29] Morten Nielsen,et al. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method , 2007, BMC Bioinformatics.
[30] M. Barnardo,et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). , 1995, Tissue antigens.
[31] N. Farid,et al. Well differentiated thyroid carcinoma is associated with human lymphocyte antigen D‐related 11 in Eastern Hungarians , 2005, Cancer.
[32] John Sidney,et al. Rationally Engineered Therapeutic Proteins with Reduced Immunogenicity , 2005, The Journal of Immunology.
[33] D. Baker,et al. Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes , 2014, Proceedings of the National Academy of Sciences.
[34] Julie A McMurry,et al. Epitope-driven TB vaccine development: a streamlined approach using immuno-informatics, ELISpot assays, and HLA transgenic mice. , 2007, Current molecular medicine.
[35] J. Hanley,et al. The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.
[36] John Sidney,et al. A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus Approach , 2008, PLoS Comput. Biol..
[37] T. Boone,et al. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. , 2007, Clinical immunology.
[38] Morten Nielsen,et al. NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction , 2009, BMC Bioinformatics.
[39] S. Steinberg,et al. Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression , 2013, Science Translational Medicine.
[40] Chris Bailey-Kellogg,et al. Protein deimmunization via structure‐based design enables efficient epitope deletion at high mutational loads , 2015, Biotechnology and bioengineering.
[41] Ronit Mazor,et al. Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A , 2012, Proceedings of the National Academy of Sciences.
[42] Wolfgang Aehle,et al. A β-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy , 2005, Molecular Cancer Therapeutics.
[43] R D Appel,et al. Protein identification and analysis tools in the ExPASy server. , 1999, Methods in molecular biology.
[44] S. Stevanović. Identification of tumour-associated t-cell epitopes for vaccine development , 2002, Nature Reviews Cancer.
[45] J. D. White,et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] J. Rothbard,et al. Role of the polymorphic residues in HLA-DR molecules in allele-specific binding of peptide ligands. , 1994, Journal of immunology.
[47] W. Paul,et al. How are TH2-type immune responses initiated and amplified? , 2010, Nature Reviews Immunology.
[48] David Baker,et al. Removing T-cell epitopes with computational protein design , 2014, Proceedings of the National Academy of Sciences.
[49] Chris Bailey-Kellogg,et al. Computationally driven deletion of broadly distributed T cell epitopes in a biotherapeutic candidate , 2014, Cellular and Molecular Life Sciences.
[50] Alessandro Sette,et al. Reverse vaccinology: developing vaccines in the era of genomics. , 2010, Immunity.
[51] Christine J. Bryson,et al. Immunogenicity of protein therapeutics: The key causes, consequences and challenges. , 2010, Self/nonself.
[52] A. D. De Groot,et al. Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome , 2014, Human vaccines & immunotherapeutics.
[53] W. Wilson,et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] John Sidney,et al. Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes , 2014, BCB.
[55] M. Tilanus,et al. Automated, solid-phase sequencing of DRB region genes using T7 sequencing chemistry and dye-labeled primers. , 1995, Tissue antigens.